- Home
- CBOE vs ONC Comparison
CBOE vs ONC Comparison
Compare CBOE & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBOE | ONC |
|---|---|---|
| Founded | 1973 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8B | 31.4B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | CBOE | ONC |
|---|---|---|
| Price | $299.40 | $299.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $289.44 | ★ $380.45 |
| AVG Volume (30 Days) | ★ 716.7K | 192.9K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 44.52 | N/A |
| EPS | ★ 10.42 | N/A |
| Revenue | ★ $2,229,100,000.00 | N/A |
| Revenue This Year | N/A | $747.23 |
| Revenue Next Year | $3.54 | $15.78 |
| P/E Ratio | ★ $29.07 | $614.06 |
| Revenue Growth | ★ 239.31 | N/A |
| 52 Week Low | $211.19 | $228.93 |
| 52 Week High | $309.87 | $385.22 |
Technical Indicators
Market Signals| Indicator | CBOE | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 44.59 |
| Support Level | $276.64 | $283.56 |
| Resistance Level | $307.78 | $311.10 |
| Average True Range (ATR) | 6.97 | 6.98 |
| MACD | -0.14 | -0.99 |
| Stochastic Oscillator | 60.83 | 8.44 |
Price Performance
Historical ComparisonAbout CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.